We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Lacticaseibacillus rhamnosus GG (ATCC 53103)
One of the two most-studied probiotic strains, and a case study in why strain-level evidence matters. It has one genuinely strong, guideline-endorsed use — preventing antibiotic-associated diarrhea in children — while its two most-marketed uses, treating stomach bugs and preventing eczema, were both overturned by the largest and best-run trials.
What the evidence says
Most L. rhamnosus GG studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from high-quality meta-analyses and randomised trials published 1999–2024 with a typical study size of 302 participants.
Based on 17 studies · 8 meta-analyses · 6 RCTs · 4,282 total participants
Confidence
High confidenceBy outcome
The best-characterized probiotic strain there is, with one real guideline-endorsed indication (preventing antibiotic-associated diarrhea in children) — but its two most-marketed uses, treating acute gastroenteritis and preventing eczema, were both nullified by the largest and best-conducted evidence.
4 trials ongoing or recruiting · 12 completed on ClinicalTrials.gov
1 of the completed trials have posted results
Registered trials show research momentum for L. rhamnosus GG, not proof of effect — a registration is a plan, and posted results are sponsor-reported, not peer-reviewed. They are never counted toward the evidence rating above.
Browse these trials on ClinicalTrials.govClinicalTrials.gov · as of Sep 2026
Under EU law (Reg. 1924/2006), EFSA reviews whether a specific health claim for L. rhamnosus GG meets the evidence standard. These are independent regulatory decisions on claims — not studies, and never counted toward the evidence score above.
“Not authorised” means the specific claim wording did not meet the EU’s evidence standard — often a matter of dossier or phrasing, not proof of no effect. EFSA judges marketing claims and is kept separate from our study-based evidence score.
Source: EU Register of nutrition and health claims (European Commission / EFSA) · register snapshot Feb 2013
Our research database did not respond in time, so the studies and count above cover only our curated set. This refreshes automatically.
Lacticaseibacillus rhamnosus GG (ATCC 53103, also deposited as DSM 33156) is the best-characterized probiotic strain in existence, and unusually for a probiotic its trial evidence maps cleanly onto the product you can actually buy. The evidence splits sharply by indication.
For PREVENTING antibiotic-associated diarrhea in children it earns a strong ESPGHAN recommendation at moderate quality of evidence: a meta-analysis pooling 11 RCTs (n=1,308) found risk falling from 22.4% to 12.3%. It also cuts healthcare-associated diarrhea and symptomatic rotavirus in hospitalized children.
But for TREATING acute gastroenteritis — the use it is most often sold for — a 971-child NEJM trial was flatly null on every outcome, and the 2020 Cochrane review reached the same conclusion in its LGG-specific analysis while explicitly demonstrating publication bias on funnel plots.
Eczema prevention tells the same story: the famous 2001 Lancet trial halved eczema risk in high-risk infants, but pooled analysis of five RCTs at high-to-moderate certainty found no effect, meaning that landmark result did not replicate. Adult evidence is weak apart from H. pylori eradication regimens.
Safety is excellent in healthy people, with the important exception of immunocompromised and critically ill patients, where genuine bloodstream infections with this strain have been documented.
A human gut-derived strain that adheres to intestinal mucosa and transiently colonizes, helping restore the colonization resistance that antibiotics disrupt. This is the mechanistic basis for its one strong indication.
In a 62-pair trial, maternal supplementation during pregnancy and lactation raised the anti-inflammatory cytokine TGF-beta2 in breast milk (2885 vs 1340 pg/mL, P=0.018) — the proposed pathway behind the atopy hypothesis, which pooled trials later failed to confirm.
Proposed to influence intestinal permeability and the mucosal immune response. Measured microbial-metabolism markers changed similarly in probiotic and placebo arms in one trial, so this mechanism is not firmly established in humans.
How L. rhamnosus GG works — from molecular targets to health outcomes. Click an edge to see supporting research.This visualization is in beta — pathways are being refined and expanded.
Avoid unless a clinician directs otherwise — this is where the documented bloodstream infections occur.
The best-studied group and consistently well tolerated; this is also where the efficacy evidence is strongest.
A strain-specific meta-analysis found lower NEC stage >=II (RR 0.50, 5 RCTs, n=851) with no difference in late-onset sepsis or mortality, but this belongs in a supervised neonatal setting, not consumer self-use.
Given prenatally and postnatally in trials with no adverse signal, but no dedicated pregnancy safety study exists. Discuss with a clinician.
Antibiotics can kill the organism and reduce its effect — though the pediatric prevention trials dosed both concurrently and still showed benefit.
Not an interaction with the drug itself, but immunosuppression is the main risk factor for the documented bloodstream infections with this strain. Avoid unless a clinician advises otherwise.
Tip: Usually settles within the first week
Tip: Essentially confined to immunocompromised and critically ill patients; avoid in those groups
L. rhamnosus GG has an evidence score of 6/10 — moderate evidence based on 44 indexed studies, including 8 meta-analyses. One of the two most-studied probiotic strains, and a case study in why strain-level evidence matters. It has one genuinely strong, guideline-endorsed use — preventing antibiotic-associated diarrhea in children — while its two most-marketed uses, treating stomach bugs and preventing eczema, were both overturned by the largest and best-run trials. Representative study: PMID 33295643.
The commonly studied dose of L. rhamnosus GG is 10-20 billion CFU (1-2 x 10^10) daily; 10 billion CFU/day is the effective floor. Individual needs vary — start at the lower end of the range and adjust based on how you respond.
Timing is flexible for L. rhamnosus GG — consistent daily use matters more than the time of day. Trials dosed once or twice daily without a specified interval from the antibiotic dose.
L. rhamnosus GG is generally well-tolerated and considered safe for most healthy adults at recommended doses. Reported side effects are uncommon and include mild gas or bloating, bloodstream infection (bacteremia). Use caution if any of these apply to you: Immunocompromise or immunosuppression (transplant, chemotherapy, advanced HIV); Critical illness / ICU admission; Indwelling central venous catheter.
Probiotics
Likely helpsLive microorganisms where strain selection determines outcome — Lactobacillus and Bifidobacterium strains best studied for gut, immune, and mood.
Saccharomyces Boulardii
Likely helpsAntibiotic-resistant probiotic yeast that supports digestive regularity and gut flora during travel and antibiotic use.
L. casei Shirota
Mostly mechanism / observationalThe Yakult strain — the most-trialled single probiotic strain of the three psychobiotic-adjacent contenders, and a clear illustration of why trial size matters. The two largest trials (n=737 and n=359) were null on their primary endpoints. The positives cluster in smaller, Yakult-affiliated studies that compared fermented milk against plain milk.
L. plantarum 299v
Mostly mechanism / observationalThe one probiotic strain with a genuinely distinctive trick: taken with a meal it increases non-heme iron absorption by roughly 50%, replicated across independent dual-isotope studies. Its IBS evidence is far weaker — rated low certainty, with one clearly negative trial — and it does not fix iron deficiency on its own.
Explore: Best supplements for Body HealthBest supplements for Vitality & Longevity
Reviewed by Dr. Baher Al Hakim · Last reviewed July 2026 · evidence from 17 studies · how we score · editorial policy
This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication.
Tap node to isolate • Pinch to zoom • Tap edge for research